47 results about "ERCC1" patented technology

The present invention relates to prognostic methods which are useful in medicine, particularly cancer chemotherapy. The object of the invention to provide a method for assessing TS and/or ERCC1 expression levels in fixed or fixed and paraffin embedded tissues and prognosticate the probable resistance of a patient's tumor to treatment with 5-FU and oxaliplatin-based therapies by examination of the amount of TS and/or ERCC1 mRNA in a patient's tumor cells and comparing it to a predetermined threshold expression level for those genes. More specifically, the invention provides to oligonucleotide primer pairs ERCC1 and TS and methods comprising their use for detecting levels of ERCC1 and TS mRNA, respectively.

The present invention relates to prognostic methods which are useful in medicine, particularly cancer chemotherapy. The object of the invention to provide a method for assessing ERCC1 expression levels in fixed or fixed and paraffin embedded tissues and determine a platinum-based chemotherapy by examination of the amount of ERCC1 mRNA in a patient's tumor cells and comparing it to a predetermined threshold expression level. More specifically, the invention provides to oligonucleotide primer pair ERCC1 and methods comprising their use for detecting levels of ERCC1 mRNA.

The protein EGFR, ERCC1, RRM1, thymidylate synthase, or beta-tubulin from cancer cells is detected in a blood sample by enriching the cancer cells from the blood sample followed by performing on the enriched cancer cells an immunoassay capable of detecting the proteins mentioned above. Cancer patients overexpressing EGFR are treated with an anti-EGFR agent, for example cetuximab, panitumumab, erlotinib or gefitinib.

The invention relates to a multiple-gene detecting kit related to antitumor drugs. The multiple-gene detecting kit comprises a mixture of RT (reverse transcription) primers and a mixture of PCR (polymerase chain reaction) amplification primers, wherein each RT primer and each PCR amplification primer based on genetic groups, reference genes and a reaction internal label are respectively contained in each of the mixture of the RT primers and the mixture of the PCR amplification primers; the multiple-gene detecting kit is characterized in that the genetic groups comprise PTEN, EGFR, DPYD, HER2, RRM1, ERCC1, TUBB3, TOP1, TYMS and TOP2A; the reference genes comprise ACTB, GAPDH and B2M; the reaction internal label is KAN-rRNA (ribosomal RNA). The multiple-gene detecting kit related to antitumor drugs disclosed by the invention can be used for systemically detecting the expression level of a plurality of genes closely related to the antitumor drugs by one step, is simple and convenient to use, good in accuracy and high in detecting efficiency, and can be used for guiding chemotherapy drugs and selecting chemotherapy regimens very well.

Methods are provided for quantifying the ENT1, ERCC1, FOLR1, RRM1, TUBB3, TOPO1, and/or TOPO2A proteins directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM)/Multiple Reaction Monitoring (MRM) mass spectrometry. The biological samples are treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks. A protein digest is prepared from a biological sample and the ENT1, ERCC1, FOLR1, RRM1, TUBB3, TOPO1, and/or TOPO2A proteins are quantitated in the digest by quantitating in the protein sample one or more of the peptides described by the method of SRM/MRM mass spectrometry.

The invention relates to a real-time PCR detecting method of tumor-associated gene mutation and reagent system, belonging to medicine curative effect detecting technical field. The tumour repair genes XRCC3, ERCC1 and ERCC2 associated with the tumour individualized theraphy are used as target genes to detect, and the customed designed special oligonucleotide primer sequence, hydrolysis probe and Taqman-MGB detection agent system are used and using real-time quantitative PCR method, therefore the mutation of special site of the tumor-associated gene is detected wherein the agent system is just the real-time quantitative PCR agent system comprising any oligonucleotide primer sequence and probe. The method can be used for effect detection of the clinical individualized medication scheme.

The invention relates to a primer group, reagent and/or kit and system for detecting lung cancer chemotherapy related genes, and application. The primer group contains primers for detecting gene mutation of ERCC1, MTHFR, GSTP1, XRCC1, DYNC2H1, ABCB1, CYP2C8*3, TP53, NQO1, CBR3, SOD2, CYP2C19, UGT1A1*6, TYMS, NT5C2 and CDA. The primer group, the reagent and/or the kit, the system and the application have the advantages of high accuracy, high specificity, high sensitivity, good precision and the like, and meanwhile, further have the advantages of sample saving, short detection period, easy operation, convenient analysis and the like.

The invention provides a kit for detecting the expression level of ERCC1 (excision repair cross complementation 1). By adopting a fluorescent quantitative PCR (polymerase chain reaction) platform, and taking RNA (ribonucleic acid) reserved by culture cells as external calibration RNA and GapDH (reduced glyceraldehydes-phosphate dehydrogenase) as data of internal contrast gene normalization processing experiments, relative quantitative detection is carried out on the level of mRNA (messenger ribose nucleic acid) of ERCC1 of a sample tissue through a TaqMan probe method. The kit can be used for detecting the expression quantity of the ERCC1 at a level of mRNA and can reflect the gene expression level more truly; the detection data of the fluorescent quantitative PCR method is output by a machine, thus avoiding subjective identification of people and being more objective; the cultured cells are taken as the external RNA calibrator, and the whole process and the fluorescent quantitative PCR experiment are synchronous, so that the errors caused by the experiment process is reduced, the determination of the clinical cut-off value is realized, furthermore, the fluorescent quantitative PCR method for detecting the level of mRNA of ERCC1 is realized to be used in clinic.

The present invention concerns an in vitro method for detecting the susceptibility of a tumor cell to a chemotherapy, said method comprising the step of the measurement of the ERCC1 protein by immunohistochemistry in a formalin-fixed paraffin-embedded tumor sample.

Methods are provided for identifying whether a lung tumor will be responsive to treatment with the combination of the therapeutic agents cisplatin and pemetrexed. Specified ERCC1, TS, p16, and FRα fragment peptides are precisely detected and quantitated by SRM-mass spectrometry directly in lung tumor cells collected from lung tumor tissue that was obtained from a cancer patient and compared to reference levels in order to determine if the lung cancer patient will positively respond to treatment with the combination of cisplatin and pemetrexed therapeutic agents.

The invention relates to a monoclonal antibody 2E12 capable of specifically bonding excision repair cross complementing action group 1 (ERCC1) protein, generated hybridoma of the monoclonal antibody, a composition of the monoclonal antibody, and a usage method and an application of the monoclonal antibody. The monoclonal antibody 2E12 can overcome the non-specificity problem of ERCC1 monoclonal antibody 8F1, can be used for prognosis of tumors such as non-small cell lung cancer, ovary cancer, breast cancer, renal adenocarcinoma, endometrial carcinoma, and can realize the curative effect prediction for auxiliary chemotherapy with platinum containing chemotherapeutics.

The invention belongs to the technical field of biological detection, and provides a primer for simultaneously detecting XRCC1, ERCC1 and GSTP1 gene polymorphisms. The primer comprises a PCR amplification primer and a SNaPshot PCR primer. The primer can achieve specific detection on XRCC1, ERCC1 and GSTP1 gene polymorphisms, causes no cross reaction and is good in accuracy.

The present invention discloses a reagent kit which detects the genetic susceptibility of the synthetic disease of adult woman. The reagent kit comprises a specific primer pair and a specific fluorescent probe pairs which simultaneously detects the SNP polymorphic genotype on the genes of CYBA, CAT, LPL, LEP, ADIPOQ, SOD3, IL3, NOS3, CTLA4, ENOS, ESR2, ERCC1, MTHFR, MS4A2, XRCC1, ALDH2, TNFA, MTR, CCL5, COMT, GSTP1, PPARG, PARP1, OPG, VDR, PON1, ABCA1, MTRR, ERCC2, AT1R, AGT, CCND1, UCP2, ADH2, ADBR2, APOB, CYP11B2, CYP1A1, CYP2E1, CETP, NQO1, IL6, CYP2A13, CBS, a routine component which is used for the fluorescent quantitative PCR testing and the like. The reagent kit of the invention evaluates the genetic susceptibility of the synthetic disease of adult woman through simultaneously detecting the mononucleotide polymorphism site genotype which is closely linked to the genetic susceptibility of the synthetic disease of adult woman.

The invention is a technology for performing allele specific amplification by using a labeled primer on the basis of PCR (polymerase chain reaction) amplification of a target template, and eventually detecting the 118th codon of an ERCC1 (excision repair cross complement) by a nucleic acid test strip method. The main detection principle is as follows: according to immunological specific binding of an antigen and a specific antibody thereof, a nucleic acid fragment is fixed on the nucleic acid detection test strip, and then according to color development of visual colorimetric latex particles on the test strip, a result is detected. In the technology for detecting polymorphic genotypes of the 118th codon of the ERCC1 by the PCR & AS-PCR nucleic acid test strip method, a specific PCR amplification primer for PCR amplification, an allele-specific primer with a biotin label at 5' end, and a specific probe with an FITC (fluorescein isothiocyanate) label at 3' end are mainly used.

The present invention provides a kit for detecting genetic predisposition of adult male syndrome. The kit includes specific primer pairs and specific fluorescent probe pairs for detecting 48 SNP polymorphism genotypes on the genes LPL, TNF-alpha, LEP, ADIPOQ, SOD3, IL3, CTLA4, ENOS, ESR2, ERCC1, MTHFR, MS4A2, XRCC1, ALDH2, TNFA, MTR, CCL5, COMT, GSTP1, PPARG, PARP1, OPG, VDR, PON1, ABCA1, MTRR, ERCC2, AT1R, AGT, CCND1, UCP2, ADH2, ADBR2, APOB, CYP11B2, CYP1A1, CYP2E1, CETP, NQO1, IL6, CYP2A13 at the same time, and normal components for FQ-PCR detection. The kit of the invention evaluates the genetic predisposition of adult male syndrome by detecting the genotypes of the 48 SNP polymorphism sites at the same time which is tightly relative to the genetic predisposition of adult male syndrome.

The invention discloses a kit for platinum drug medication guidance. The invention protects a primer group. The primer group comprises a primer pair A, a primer pair B and a primer pair C. The primer pair A comprises a single chain DNA molecule shown in the sequence 1 and a single chain DNA molecule shown in the sequence 2. The primer pair B comprises a single chain DNA molecule shown in the sequence 3 and a single chain DNA molecule shown in the sequence 4. The primer pair C comprises a single chain DNA molecule shown in the sequence 5 and a single chain DNA molecule shown in the sequence 6. The invention also protects a kit for identification of C118T point mutation of an ERCC1 gene, R194W point mutation of a XRCC1 gene and I105V point mutation of a GSTP1 gene. The kit comprises the primer group. The kit can be used for detecting three platinum drug sensitivity-related SNP sites, can be further used for platinum drug individual use guidance and improves clinical treatment specificity and predictability.

The present invention provides a kit of detecting genetic predisposition of children syndrome. The kit includes specific primer pairs and specific fluorescent probe pairs for detecting 28 SNP polymorphism genotypes on the genes NOS3, CTLA4, ENOS, ERCC1, ERCC2, MTHFR, MTRR, MTR, MS4A2, XRCC1, ALDH2, TNFA, CCL5, PARP1, OPG, VDR, PON1, AGT, CCND1, UCP2, ADH2, ADBR2, APOB, CYP11B2, CYP1A1, CYP2E1, CETP, NQO1 at the same time, and normal components for FQ-PCR detection. The kit of the invention evaluates the genetic predisposition of children syndrome by detecting the genotypes of the 28 SNP polymorphism sites at the same time which is tightly relative to the genetic predisposition of children syndrome.

The invention discloses a new application of astragalus polysaccharide, and belongs to the technical field of biology medicine. A basis is provided for preventing and treating myoblastosis through radix astragali. The inventor of the invention finds that the astragalus polysaccharide can obviously reinforce the proliferation activity of human BM-MSCs in formaldehyde environment, and can reduce DNAfragmentation and DPCs formation of human BM-MSCs induced by formaldehyde so as to have good protection effects. The astragalus polysaccharide can promote DNA injury repair factors of XPA, XPC, ERCC1, RPA1 and RPA2 mRNA and protein expression, and improve DNA damage repair capacity. The inventor finds that the astragalus polysaccharide can reinforce the proliferation activity of human BM-MSCs inthe formaldehyde environment for the first time, can reduce the DNA fragmentation effects of the human BM-MSCs in the formaldehyde environment and can reduce the DPCs formation of the human BM-MSCs inthe formaldehyde environment.